Concise Prescribing Info
Rabeprazole Na
Active duodenal, active benign gastric & anastomotic ulcers. Erosive or ulcerative GERD, GERD long-term management (GERD maintenance), symptomatic treatment of moderate to very severe GERD, Zollinger-Ellison syndrome & other pathological hypersecretory conditions. In combination w/ appropriate antibacterial therapeutic regimens for eradication of H. pylori in patients w/ PUD. Prevention of gastric & duodenal ulcer recurrence associated w/ low-dose aspirin therapy.
Dosage/Direction for Use
Adult & elderly Active duodenal, active benign gastric & anastomotic ulcers 10-20 mg once daily in the morning. Erosive or ulcerative GERD 10-20 mg once daily for 4-8 wk. Reflux esophagitis patients 10-20 mg bid for a further 8 wk, when proton-pump inhibitor treatment is ineffective. Patients w/ severe mucosa injury 20 mg bid. GERD maintenance Maintenance: 10-20 mg once daily depending upon patient response. Symptomatic treatment of moderate to very severe GERD 10 mg once daily. When symptom has resolved, use as on-demand regimen for subsequent symptom control. Zollinger-Ellison syndrome Individualized dosage. Initially 60 mg daily. Doses up to 100 mg daily or 60 mg bid have been used. Eradication of H. pylori Pariet 20 mg bid + clarithromycin 500 mg bid + amoxicillin 1 g bid for 7 days. Adult Prevention of gastric & duodenal ulcer associated w/ low-dose aspirin therapy 10 mg once daily. Adolescent ≥12 yr Short-term (up to 8 wk) treatment of GERD 20 mg once daily up to 8 wk.
May be taken with or without food: Swallow whole, do not chew/crush.
Hypersensitivity to rabeprazole Na or substituted benzimidazoles.
Special Precautions
Exclude gastric or esophageal malignancy prior to treatment. Regularly monitor patients on long-term treatment. Severe hepatic dysfunction. Symptomatic & asymptomatic hypomagnesemia. Monitor Mg levels prior to initiation of proton-pump inhibitors treatment & periodically in patients expected to be on prolonged treatment or in concomitant use w/ digoxin or diuretics. Risk of osteoporosis-related fractures & GI infections eg, C. difficile. Concomitant use w/ methotrexate. May affect ability to drive or operate machinery. Pregnancy & lactation. Childn <12 yr.
Adverse Reactions
Infection; insomnia; headache, dizziness; cough, pharyngitis, rhinitis; diarrhea, vomiting, nausea, abdominal pain, constipation, flatulence; non-specific pain/back pain; asthenia, flu-like syndrome.
Drug Interactions
Decrease antifungal plasma levels of ketoconazole or itraconazole. May reduce exposure of atazanavir. May elevate & prolong serum levels of methotrexate.
ATC Classification
A02BC04 - rabeprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Pariet EC tab 20 mg
14's;20 × 14's
Pariet EC tab 10 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in